Two Sigma Advisers
AUTL

Two Sigma Advisers’s Autolus Therapeutics AUTL Stock Holding History

Two Sigma Advisers’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-164,700
Closed -$255K – 2320
2025
Q1 		$255K Sell
164,700
-168,700
-51% -$342K ﹤0.01% 2050
2024
Q4 		$783K Buy
333,400
+15,400
+5% +$52.1K ﹤0.01% 1571
2024
Q3 		$1.15M Buy
318,000
+61,300
+24% +$244K ﹤0.01% 1348
2024
Q2 		$893K Buy
256,700
+225,600
+725% +$974K ﹤0.01% 1604
2024
Q1 		$198K Buy
31,100
+1,500
+5% +$9.36K ﹤0.01% 2216
2023
Q4 		$191K Buy
29,600
+4,500
+18% +$17.2K ﹤0.01% 2244
2023
Q3 		$58.5K Sell
25,100
-1,300
-5% -$3.7K ﹤0.01% 2263
2023
Q2 		$62.8K Buy
26,400
+12,700
+93% +$30.1K ﹤0.01% 2252
2023
Q1 		$25.2K Buy
+13,700
New +$26.8K ﹤0.01% 2507
2021
Q2 		– Sell
-13,900
Closed -$80K – 2444
2021
Q1 		$80K Buy
+13,900
New +$103K ﹤0.01% 2463

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Two Sigma Advisers's AUTL Position: Q2 2025 in Review

Two Sigma Advisers sold out of Autolus Therapeutics (AUTL) in Q2 2025, closing a stake of 164,700 shares — an estimated $255K sold.

Two Sigma Advisers first reported a position in AUTL in Q1 2021 and held it in 10 quarters. The position peaked at $1.15M in Q3 2024. 94 funds tracked by Wall St. Rank hold AUTL as of Q2 2025.

  • Two Sigma Advisers reported no remaining Autolus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 164,700 Autolus Therapeutics shares in Q2 2025, an estimated $255K.
  • Two Sigma Advisers first reported a position in Autolus Therapeutics in Q1 2021 and held it in 10 quarters.
  • Two Sigma Advisers's Autolus Therapeutics position peaked at $1.15M in Q3 2024.
  • 94 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.